News Column

Biologix Hair to Exhibit at 7th World Congress for Hair Research and International Investigative Dermatology Conference, Edinburgh, Scotland

Page 2 of 1

LogoTracker

TORONTO, ONTARIO -- (Marketwired) -- 04/26/13 -- Biologix Hair Inc. (OTCBB: BLGX) (OTCQB: BLGX) announces that senior executives from the Company's Clinician Licensing Department will be exhibiting the Biologix Hair Therapy System™ to attendees of two international medical conferences in Edinburgh, Scotland. The first conference Biologix will attend is the 7th World Congress for Hair Research May 4 - 6, followed immediately by the 6th International Investigative Dermatology Meeting May 8 - 11. Both events are to be held at the Edinburgh International Conference Centre.

Donna Lieder, Biologix Hair Inc. Vice President of Clinician Licensing, commented, "We have had great success in expanding the awareness of our patent-pending breakthrough hair therapy system at major medical conferences around the world. We anticipate both the 7th World Congress for Hair Research and the 6th International Investigative Dermatology Conference will be marquee opportunities for Biologix to continue to develop our rapidly growing international network of contracting clinicians seeking to secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™."

The 7th World Congress for Hair Research

This joint meeting of the European, North American, Japanese, Korean, Indian and Australian Hair Research Societies is the pre-eminent triennial gathering for physicians, scientists and others interested in hair. Again this year, attendees can expect an innovative and stimulating scientific programme as basic and clinical hair research continue to expand. Up and coming young clinicians and scientists are encouraged to present, as are research groups within the industry.

Beginning Saturday, 4 May, and running through the evening of Monday, 6 May, individual speakers, concurrent sessions, industry sponsored symposia, workshops, plenary sessions and exciting social events will be offered. This year's location in Edinburgh, the capital of Scotland, offers attendees amazing opportunities for sightseeing, learning and experiencing the culture of this ancient city as well as a wide variety of choices for accommodation. More information about the 7th World Congress for Hair Research is at http://Hair2013.org.

The 6th International Investigative Dermatology (IID) Meeting

The IID Meeting, held once every five years, is organized by three societies: the European Society for Dermatological Research (ESDR), the Society for Investigative Dermatology (SID) and the Japanese Society for Investigative Dermatology JSID, in coordination with the local organizing committee in Edinburgh. IID2013's format is structured to allow for not only exciting science presentations but also for collegiality and quality social interaction. The attendance of internationally renowned scientists is sure to stimulate frequent lively, engaging exchange about cutting-edge scientific information. Travel grants have been made available to encourage attendance by young scientists in order to encourage their participation at IID2013.

Satellite meetings will precede the official conference opening, from noon on Tuesday, 7 May until 5pm on 8 May, after which the conference will run through Saturday, 11 May. Concurrent sessions will offer attendees a broad choice of topics interspersed with lectures by a sterling lineup of the world's top dermatology scientists and clinicians. The last IID Meeting, held in 2008 in Japan, received more than 1,800 delegates from around the world, and more are expected to attend in 2013. More information about the 6th IID Meeting is at http://www.iid2013.org.

About Biologix Hair Inc. and Biologix Hair Science Ltd.

Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.

Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.

BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.

Additionally, on May 11, 2012, Venable LLC, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.

Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.

As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.

Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.

To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.

Disclaimer

This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.



Contacts:
Biologix Hair Inc.
Corporate Communications
Toll Free: +1 855.292.8585
Phone: +1 647.494.8001
CorporateCommunications@BiologixHair.com
www.BiologixHair.com



Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters